Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.

MLA

Bulen, Benjamin J., et al. “Validation of Immunotherapy Response Score as Predictive of Pan-Solid Tumor Anti-PD-1/PD-L1 Benefit.” Cancer Research Communications, vol. 3, no. 7, July 2023, pp. 1335–49. EBSCOhost, https://doi.org/10.1158/2767-9764.CRC-23-0036.

APA

Bulen, B. J., Khazanov, N. A., Hovelson, D. H., Lamb, L. E., Matrana, M., Burkard, M. E., Yang, E. S.-H., Edenfield, W. J., Claire Dees, E., Onitilo, A. A., Buchschacher, G. L., Miller, A. M., Parsons, B. M., Wassenaar, T. R., Suga, J. M., Siegel, R. D., Irvin, W., Nair, S., Slim, J. N., … Tomlins, S. A. (2023). Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit. Cancer Research Communications, 3(7), 1335–1349. https://doi.org/10.1158/2767-9764.CRC-23-0036

Chicago

Bulen, Benjamin J, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana, Mark E Burkard, Eddy Shih-Hsin Yang, et al. 2023. “Validation of Immunotherapy Response Score as Predictive of Pan-Solid Tumor Anti-PD-1/PD-L1 Benefit.” Cancer Research Communications 3 (7): 1335–49. doi:10.1158/2767-9764.CRC-23-0036.